NM_005343.4:c.35_36delGCinsTA
Variant summary
Our verdict is Pathogenic. The variant received 15 ACMG points: 15P and 0B. PS1_Very_StrongPM1PM5PP3PP5_Moderate
The NM_005343.4(HRAS):c.35_36delGCinsTA(p.Gly12Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type MNV, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Pathogenic (★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Pathogenic in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G12S) has been classified as Pathogenic.
Frequency
Consequence
NM_005343.4 missense
Scores
Clinical Significance
Conservation
Publications
- ciliary dyskinesia, primary, 39Inheritance: AR Classification: STRONG, MODERATE, LIMITED Submitted by: PanelApp Australia, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- primary ciliary dyskinesiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 15 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_005343.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| HRAS | NM_005343.4 | MANE Select | c.35_36delGCinsTA | p.Gly12Val | missense | N/A | NP_005334.1 | ||
| HRAS | NM_176795.5 | MANE Plus Clinical | c.35_36delGCinsTA | p.Gly12Val | missense | N/A | NP_789765.1 | ||
| HRAS | NM_001130442.3 | c.35_36delGCinsTA | p.Gly12Val | missense | N/A | NP_001123914.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| HRAS | ENST00000311189.8 | TSL:1 MANE Select | c.35_36delGCinsTA | p.Gly12Val | missense | N/A | ENSP00000309845.7 | ||
| HRAS | ENST00000417302.7 | TSL:5 MANE Plus Clinical | c.35_36delGCinsTA | p.Gly12Val | missense | N/A | ENSP00000388246.1 | ||
| HRAS | ENST00000493230.5 | TSL:1 | n.35_36delGCinsTA | non_coding_transcript_exon | Exon 2 of 7 | ENSP00000434023.1 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
not provided Pathogenic:1
The in-frame G12V pathogenic variant in the HRAS gene has been reported previously as a de novo variant in several unrelated individuals with a severe presentation of Costello syndrome (Burkitt-Wright et al., 2012). The G12V variant alters GTP and GDP dissociation rates resulting in increased active GTP-bound HRAS, which upregulates the Ras/MAPK pathway (Wey et al., 2013). The G12V variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G12V variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Missense variants at the same residue (G12S, G12C, G12D, G12A) as well as in nearby residues (G13C, G13D) have been reported in the Human Gene Mutation Database in association with Costello syndrome (Stenson et al., 2014), supporting the functional importance of this region of the protein. We interpret G12V as a pathogenic variant.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at